Hims & Hers(NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk(NYSE: NVO) asked the FDA to not allow companies to compound GLP-1 semaglutide. This could be a direct hit to Hims & Hers business, but the impact may not be what you think, as Travis Hoium covers in this video.
*Stock prices used were end-of-day prices of Oct. 23, 2024. The video was published on Oct. 23, 2024.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Amazon: if you invested $1,000 when we doubled down in 2010, you’d have $20,803!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $43,654!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $404,086!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
*Stock Advisor returns as of October 21, 2024
Travis Hoium has positions in Hims & Hers Health. The Motley Fool recommends CVS Health and Novo Nordisk. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
